網膜色素変性症の世界市場レポート 2025年

網膜色素変性症の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.6％で163億7,000万米ドルに成長します。予測期間の成長は、網膜再生のための幹細胞研究の進展、個別化医療アプローチ、希少疾病用医薬品開発への投資拡大、遠隔医療サービスの拡大などに起因すると考えられます。予測期間における主な動向としては、併用療法へのシフト、患者中心の臨床試験デザインの増加、価値に基づく価格設定モデルの採用、デジタル治療薬の統合などが挙げられます。

今後数年間は、ヘルスケア支出の増加が網膜色素変性症市場の拡大を牽引すると予想されます。ヘルスケア支出とは、特定の期間における治療、投薬、入院、予防医療を含むヘルスケア商品およびサービスに費やされる総額のことで、集団内の医療費全体を反映しています。この支出は、高度医療技術にかかる費用の増加、人口の高齢化、慢性疾患の蔓延などの要因により増加しています。網膜色素変性症の場合、ヘルスケアへの支出は診断技術の向上、効果的な治療法の開発、視力低下を管理するためのサポートケアに重点が置かれています。例えば、2024年1月、米国の政府機関である国立衛生研究所（National Institutes of Health）は、2022年の米国の医療費が4.1％増加し、4兆5,000億米ドルに達したと報告しました。その結果、ヘルスケア支出の増加が網膜色素変性症市場の成長に拍車をかけています。

網膜色素変性症市場の主要企業は、この病状を管理し、治癒させる可能性のある、より効果的で的を絞ったソリューションを提供するため、遺伝子治療などの革新的治療の開発に力を注いでいます。網膜色素変性症（RP）に対する遺伝子治療は、機能的な遺伝子を送り込み、病気の原因である欠陥遺伝子を置き換えたり修復したりするものです。この最先端の治療は、網膜の光受容細胞に正常な機能を回復させ、視力低下の進行を遅らせたり、食い止めたりすることを目的としています。例えば、ドイツに本社を置くバイオテクノロジー企業であるViGeneron GmbHは、2024年4月、CNGA1遺伝子の変異によって引き起こされるRPを治療するためにデザインされた遺伝子治療薬VG901の安全性、忍容性、有効性を評価するための第Ib相臨床試験を開始しました。本試験は、二塩基性CNGA1遺伝子変異による常染色体劣性遺伝性RP患者を対象に、VG901の硝子体内注射を検討する非盲検、単群、用量漸増試験です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の網膜色素変性症市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の網膜色素変性症市場：成長率分析
• 世界の網膜色素変性症市場の実績：規模と成長、2019～2024年
• 世界の網膜色素変性症市場の予測：規模と成長、2024～2029年、2034年
• 世界の網膜色素変性症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の網膜色素変性症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 常染色体劣性
• 常染色体優性
• X連鎖
• 世界の網膜色素変性症市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• ビタミンA
• ドコサヘキサエン酸（DHA）
• カルシウムチャネル遮断薬
• 遺伝子治療
• 網膜義眼
• その他
• 世界の網膜色素変性症市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 網膜電図
• 視野検査
• 遺伝子検査
• その他
• 世界の網膜色素変性症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の網膜色素変性症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• ホームケア
• その他
• 世界の網膜色素変性症市場：常染色体劣性のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 早期発症常染色体劣性網膜色素変性症
• 晩発性常染色体劣性網膜色素変性症
• 世界の網膜色素変性症市場：常染色体優性のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 早期発症常染色体優性網膜色素変性症
• 晩発性常染色体優性網膜色素変性症
• 世界の網膜色素変性症市場：X連鎖のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• X連鎖劣性網膜色素変性症
• X連鎖優性網膜色素変性症

第7章 地域別・国別分析

• 世界の網膜色素変性症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の網膜色素変性症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜色素変性症市場：競合情勢
• 網膜色素変性症市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sun Pharmaceutical Industries Ltd
• Spark Therapeutics
• REGENXBIO Inc.
• Editas Medicine
• IVERIC bio
• MeiraGTx Holdings
• Gensight Biologics
• Second Sight Medical Products
• Copernicus Therapeutics Inc.
• Kiora Pharmaceuticals
• 4D Molecular Therapeutics
• ReNeuron Group
• Acucela Inc.
• AGTC（Applied Genetic Technologies Corporation）
• Editgene

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 網膜色素変性症市場2029：新たな機会を提供する国
• 網膜色素変性症市場2029：新たな機会を提供するセグメント
• 網膜色素変性症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Retinitis pigmentosa (RP) is a group of inherited disorders that cause progressive degeneration of the retina, leading to vision loss. It primarily affects photoreceptor cells (rods and cones), resulting in symptoms such as night blindness and tunnel vision. Over time, RP can lead to significant visual impairment and blindness.

The main types of retinitis pigmentosa include autosomal recessive, autosomal dominant, and X-linked. Autosomal recessive retinitis pigmentosa (AR-RP) is a form of the disease where a person must inherit two copies of the mutated gene, one from each parent, to be affected. Treatment options for retinitis pigmentosa include vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, and retinal eye prosthetics, among others. The condition is diagnosed using methods such as electroretinogram, visual field testing, and genetic testing. Distribution channels for treatments include hospital pharmacies, retail pharmacies, and online pharmacies, and these treatments are utilized by various end-users such as hospitals, specialty clinics, and home care providers.

The retinitis pigmentosa market research report is one of a series of new reports from The Business Research Company that provides retinitis pigmentosa market statistics, including retinitis pigmentosa industry global market size, regional shares, competitors with a retinitis pigmentosa market share, detailed retinitis pigmentosa market segments, market trends and opportunities, and any further data you may need to thrive in the retinitis pigmentosa industry. This retinitis pigmentosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinitis pigmentosa market size has grown strongly in recent years. It will grow from $11.32 billion in 2024 to $12.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to genetic research advancements, the development of retinal imaging technologies, increased awareness campaigns, growing patient advocacy groups, and the expansion of clinical trial networks.

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $16.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to advancements in stem cell research for retinal regeneration, personalized medicine approaches, increased investment in orphan drug development, and expansion of telemedicine services. Major trends in the forecast period include a shift towards combination therapies, a rise in patient-centric clinical trial designs, the adoption of value-based pricing models, and the integration of digital therapeutics.

The growth of healthcare expenditure is expected to drive the expansion of the retinitis pigmentosa market in the coming years. Healthcare expenditure refers to the total amount spent on healthcare goods and services, which include medical treatments, medications, hospitalizations, and preventive care over a specific period, reflecting the overall cost of healthcare within a population. This expenditure is rising due to factors such as the increasing costs of advanced medical technologies, aging populations, and the growing prevalence of chronic diseases. In the case of retinitis pigmentosa, healthcare spending is focused on enhancing diagnostic techniques, developing effective treatments, and providing supportive care for managing vision loss. For example, in January 2024, the National Institutes of Health, a US-based government agency, reported that healthcare expenditure in the United States increased by 4.1% in 2022, reaching $4.5 trillion-this growth rate was faster than the 3.2% increase seen in 2021. As a result, the rising healthcare expenditure is fueling the growth of the retinitis pigmentosa market.

Leading companies in the retinitis pigmentosa market are increasingly focusing on developing innovative treatments, such as gene therapy, to provide more effective and targeted solutions for managing and potentially curing this debilitating condition. Gene therapy for retinitis pigmentosa (RP) involves delivering functional genes to replace or repair the defective ones causing the disease. This cutting-edge treatment aims to restore normal function to the affected photoreceptor cells in the retina, thereby slowing or potentially halting the progression of vision loss. For instance, in April 2024, ViGeneron GmbH, a biotechnology company based in Germany, initiated a Phase Ib clinical trial to evaluate the safety, tolerability, and efficacy of VG901, a gene therapy designed to treat RP caused by mutations in the CNGA1 gene. This trial is an open-label, single-arm, dose-escalation study investigating the intravitreal injection of VG901 in patients with autosomal recessive RP due to biallelic CNGA1 mutations.

In December 2023, Thea Pharma Inc., a pharmaceutical company based in France, acquired two antisense oligonucleotide (AON) treatments, Sepofarsen (LCA10) and Ultevursen (USH2A), from ProQR Therapeutics NV for an undisclosed amount. This acquisition aligns with Thea's focus on rare genetic eye diseases and ophthalmology. ProQR Therapeutics NV, a biotechnology company based in the Netherlands, specializes in developing treatments for retinitis pigmentosa.

Major companies operating in the retinitis pigmentosa market are Johnson & Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, ReNeuron Group, Acucela Inc., AGTC (Applied Genetic Technologies Corporation), Editgene

North America was the largest region in the retinitis pigmentosa market in 2024. The regions covered in the retinitis pigmentosa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinitis pigmentosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinitis pigmentosa market consists of revenues earned by entities by providing services such as genetic counseling, low vision therapy, psychological support, and educational support. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinitis pigmentosa market also includes sales of retinal implants, screen readers, telescopic glasses, and adaptive lighting. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinitis Pigmentosa Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinitis pigmentosa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinitis pigmentosa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinitis pigmentosa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Autosomal Recessive; Autosomal Dominant; X-Linked
• 2) By Treatment: Vitamin A; Docosahexaenoic Acid (DHA); Calcium Channel Blockers; Gene Therapy; Retinal Eye Prosthetics; Other Treatments
• 3) By Diagnosis: Electroretinogram; Visual Field Testing; Genetic Testing; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-users: Hospitals; Specialty Clinics; Homecare; Other End-users
• Subsegments:
• 1) By Autosomal Recessive: Early-Onset Autosomal Recessive Retinitis Pigmentosa; Late-Onset Autosomal Recessive Retinitis Pigmentosa
• 2) By Autosomal Dominant: Early-Onset Autosomal Dominant Retinitis Pigmentosa; Late-Onset Autosomal Dominant Retinitis Pigmentosa
• 3) By X-Linked: X-Linked Recessive Retinitis Pigmentosa; X-Linked Dominant Retinitis Pigmentosa
• Companies Mentioned: Johnson & Johnson; Novartis AG; AbbVie Inc.; Astellas Pharma Inc.; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinitis Pigmentosa Market Characteristics

3. Retinitis Pigmentosa Market Trends And Strategies

4. Retinitis Pigmentosa Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Retinitis Pigmentosa Growth Analysis And Strategic Analysis Framework

• 5.1. Global Retinitis Pigmentosa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Retinitis Pigmentosa Market Growth Rate Analysis
• 5.4. Global Retinitis Pigmentosa Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Retinitis Pigmentosa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Retinitis Pigmentosa Total Addressable Market (TAM)

6. Retinitis Pigmentosa Market Segmentation

• 6.1. Global Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autosomal Recessive
• Autosomal Dominant
• X-Linked
• 6.2. Global Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin A
• Docosahexaenoic Acid (DHA)
• Calcium Channel Blockers
• Gene Therapy
• Retinal Eye Prosthetics
• Other Treatments
• 6.3. Global Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electroretinogram
• Visual Field Testing
• Genetic Testing
• Other Diagnosis
• 6.4. Global Retinitis Pigmentosa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-users
• 6.6. Global Retinitis Pigmentosa Market, Sub-Segmentation Of Autosomal Recessive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset Autosomal Recessive Retinitis Pigmentosa
• Late-Onset Autosomal Recessive Retinitis Pigmentosa
• 6.7. Global Retinitis Pigmentosa Market, Sub-Segmentation Of Autosomal Dominant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset Autosomal Dominant Retinitis Pigmentosa
• Late-Onset Autosomal Dominant Retinitis Pigmentosa
• 6.8. Global Retinitis Pigmentosa Market, Sub-Segmentation Of X-Linked, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• X-Linked Recessive Retinitis Pigmentosa
• X-Linked Dominant Retinitis Pigmentosa

7. Retinitis Pigmentosa Market Regional And Country Analysis

• 7.1. Global Retinitis Pigmentosa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Retinitis Pigmentosa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Retinitis Pigmentosa Market

• 8.1. Asia-Pacific Retinitis Pigmentosa Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Retinitis Pigmentosa Market

• 9.1. China Retinitis Pigmentosa Market Overview
• 9.2. China Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Retinitis Pigmentosa Market

• 10.1. India Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Retinitis Pigmentosa Market

• 11.1. Japan Retinitis Pigmentosa Market Overview
• 11.2. Japan Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Retinitis Pigmentosa Market

• 12.1. Australia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Retinitis Pigmentosa Market

• 13.1. Indonesia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Retinitis Pigmentosa Market

• 14.1. South Korea Retinitis Pigmentosa Market Overview
• 14.2. South Korea Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Retinitis Pigmentosa Market

• 15.1. Western Europe Retinitis Pigmentosa Market Overview
• 15.2. Western Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Retinitis Pigmentosa Market

• 16.1. UK Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Retinitis Pigmentosa Market

• 17.1. Germany Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Retinitis Pigmentosa Market

• 18.1. France Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Retinitis Pigmentosa Market

• 19.1. Italy Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Retinitis Pigmentosa Market

• 20.1. Spain Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Retinitis Pigmentosa Market

• 21.1. Eastern Europe Retinitis Pigmentosa Market Overview
• 21.2. Eastern Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Retinitis Pigmentosa Market

• 22.1. Russia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Retinitis Pigmentosa Market

• 23.1. North America Retinitis Pigmentosa Market Overview
• 23.2. North America Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Retinitis Pigmentosa Market

• 24.1. USA Retinitis Pigmentosa Market Overview
• 24.2. USA Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Retinitis Pigmentosa Market

• 25.1. Canada Retinitis Pigmentosa Market Overview
• 25.2. Canada Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Retinitis Pigmentosa Market

• 26.1. South America Retinitis Pigmentosa Market Overview
• 26.2. South America Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Retinitis Pigmentosa Market

• 27.1. Brazil Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Retinitis Pigmentosa Market

• 28.1. Middle East Retinitis Pigmentosa Market Overview
• 28.2. Middle East Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Retinitis Pigmentosa Market

• 29.1. Africa Retinitis Pigmentosa Market Overview
• 29.2. Africa Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Retinitis Pigmentosa Market Competitive Landscape And Company Profiles

• 30.1. Retinitis Pigmentosa Market Competitive Landscape
• 30.2. Retinitis Pigmentosa Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Retinitis Pigmentosa Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Ltd
• 31.2. Spark Therapeutics
• 31.3. REGENXBIO Inc.
• 31.4. Editas Medicine
• 31.5. IVERIC bio
• 31.6. MeiraGTx Holdings
• 31.7. Gensight Biologics
• 31.8. Second Sight Medical Products
• 31.9. Copernicus Therapeutics Inc.
• 31.10. Kiora Pharmaceuticals
• 31.11. 4D Molecular Therapeutics
• 31.12. ReNeuron Group
• 31.13. Acucela Inc.
• 31.14. AGTC (Applied Genetic Technologies Corporation)
• 31.15. Editgene

32. Global Retinitis Pigmentosa Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Retinitis Pigmentosa Market

34. Recent Developments In The Retinitis Pigmentosa Market

35. Retinitis Pigmentosa Market High Potential Countries, Segments and Strategies

• 35.1 Retinitis Pigmentosa Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Retinitis Pigmentosa Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Retinitis Pigmentosa Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer